Episode 7: Giovanni Amabile, PhD, CEO of Enthera, Developing first-in-class biologics for type 1 diabetes

TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes
23/08/2020 29 min Episodio 7
Episode 7: Giovanni Amabile, PhD, CEO of Enthera, Developing first-in-class biologics for type 1 diabetes

Listen "Episode 7: Giovanni Amabile, PhD, CEO of Enthera, Developing first-in-class biologics for type 1 diabetes"

Descargar episodio Ver en sitio original

Episode Synopsis

In this episode, Giovanni Amabile joins Monica Westley to discuss the future of Enthera. Enthera is a biotech company building a pipeline of first-in-class biologics for several autoimmune conditions, with a focus in type 1 diabetes and inflammatory bowel disease.  

More episodes of the podcast TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes

Heard on the Street: Christopher Emfinger, PhD, University of Wisconsin-Madison 16/07/2024
Heard on the Street: Jeong Hun Jo, PhD, Washington University in St. Louis 15/07/2024
Heard on the Street: Christopher Acree, PhD Candidate, Vanderbilt University Medical Center 10/07/2024
Heard on the Street: Noyonika Mukherjee, PhD, Indiana Biosciences Research Institute 10/07/2024
Heard on the Street: Debjyoti Kundu, PhD, Indiana Biosciences Research Institute 10/07/2024
Heard on the Street: Michael Kalwat, PhD, Indiana Biosciences Research Institute's Diabetes Center 10/07/2024
Heard on the Street: Bart Roep, MD, Leiden University Medical Center 26/02/2024
Heard on the Street: Noel Morgan, PhD, University of Exeter 22/02/2024
Heard on the Street: Richard Oram, PhD, University of Exeter 22/02/2024
Heard on the Street: Tim Tree, PhD, Kings College London 22/02/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA